Industry Insights

  1. Accuracy, Safety And Ease Of Use 5/12/2026

    Safety, ease of use, and accuracy guide modern medical device design, advancing through improved materials, engineering innovation, standards adoption, and user‑centered development.

  2. Effective Strategies To Minimize Product Loss During Fill Finish 5/11/2026

    Every drop of high-value biologic lost in fill finish is money left on the table. Learn practical strategies to protect your yield.

  3. Regulation Is Not Slowing Your Medical Device. Your Compliance Architecture Is. 5/4/2026

    Fragmented systems delay medical device development. Connecting lifecycle traceability into a unified compliance architecture maintains continuous audit readiness.

  4. Implementing Medium And High-Volume Drug Handling And Packaging Programs 4/23/2026

    Simplify the complexity of combination product development by partnering for integrated support across device design, industrialization, manufacturing, and final product assembly.

  5. Package With A Purpose 4/21/2026

    Packaging shapes how devices are understood, handled, and used. A human-centered approach surfaces critical info sooner, reduces errors, and strengthens safety and usability.

  6. How Regulatory Is Becoming An Increasingly Valuable Asset 4/20/2026

    Build regulatory strategy into your company from day one — not as support, but as a core driver of value, risk management, and successful commercialization.

  7. A New Standard For Production Efficiency And GxP Compliance 4/20/2026

    Traditional MES platforms were built for stable environments that no longer exist. Manufacturers are now adopting composable execution architectures to reduce friction and adapt faster.

  8. Why Composable Manufacturing Execution Is Becoming The New Standard 4/20/2026

    Low-code MES promises speed, but agility comes from ownership. Composable, no-code approaches give operations teams the ability to change workflows themselves and respond faster to disruption.

  9. 503A Vs. 503B: Turning Regulatory Complexity Into Practical Compliance 4/20/2026

    Navigating human drug compounding requires aligning Section 503A and Section 503B operations with cGMP expectations, robust quality management systems, and standing inspection readiness.

  10. Harnessing The Power Of New Approach Methodologies 4/17/2026

    Human-relevant models are reshaping safety and efficacy decisions, but impact depends on selecting the right tools, integrating evidence, and turning complex data into clear, decision‑ready insights.